Attached files
| file | filename |
|---|---|
| EX-99.2 - ASSEMBLY BIOSCIENCES, INC. | ex99-2.htm |
| EX-99.1 - ASSEMBLY BIOSCIENCES, INC. | ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 2, 2011
|
VENTRUS BIOSCIENCES, INC.
|
||
|
(Exact name of registrant as specified in its charter)
|
|
Delaware
|
001-35005
|
20-8729264
|
||
|
(State or other jurisdiction of
incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer ID Number)
|
|
99 Hudson Street, 5th Floor, New York, New York
|
10013
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Registrant’s telephone number, including area code
|
(646) 706-5208
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 7.01. Regulation FD Disclosure.
A copy of a slide presentation that Ventrus Biosciences, Inc. intends to use in industry and investor presentations is hereby furnished as Exhibit 99.1 to this report. The slide presentation will be posted on Ventrus’ website at www.ventrusbio.com.
In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in such filing.
Item 8.01. Other Events.
On May 2, 2011, Ventrus issued a press release announcing that it was adding a third treatment arm of shorter duration to its proposed pivotal Phase III study for iferanserin (VEN 309) for the treatment of hemorrhoids. The treatment arm is being added based upon a request from the U.S. Food and Drug Administration, or FDA, in its response to Ventrus’ last submission of its special protocol assessment, or SPA, for the Phase III study. A copy of the press release is attached as Exhibit 99.2 to this report and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
|
|
(d)
|
Exhibits
|
|
Exhibit No.
|
Description
|
|
|
99.1
|
Slide presentation for use in industry and investor presentations.
|
|
|
99.2
|
Press release dated May 2, 2011.
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
VENTRUS BIOSCIENCES, INC.
|
|
|
Date: May 3, 2011
|
/s/ David J. Barrett
|
|
David J. Barrett, Chief Financial Officer
|